endometriosis
Conditions
Interventions
Neiyifang formula granule + Drospirenone and Ethinylestradiol Tablets (?) placebo group:Neiyifang formula granule + Drospirenone and Ethinylestradiol Tablets (?) placebo
Drospirenone and Ethinylestradiol Tablets (?) +Neiyifang formula granule placebo group:Drospirenone and Ethinylestradiol Tablets (?) +Neiyifang formula granule placebo
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: ? All cases should meet EM clinical diagnostic criteria and TCM diagnostic criteria of congealing cold blood stasis syndrome; ? 18-40 years old; ? Menstrual cycle between 21 and 35 days, period of 3 to 7 days; (4) VAS score =3, and pain must be continuous or recurrent for at least 6 months; ? Those who voluntarily participated in the experiment and signed the informed consent; ? Those who have not been treated with Western medicine or have been treated with western medicine but have stopped taking medicine for 3 months.
Exclusion criteria
Exclusion criteria: 1) patients with adenomyosis; 2) Patients with serious diseases such as cardiovascular, cerebrovascular, liver, kidney, diabetes and tumor; 3) Mental illness and long-term alcohol or drug use affect cognition; 4) Patients with chronic pelvic pain caused by anxiety and depression (depression scale and anxiety scale =50 points). (Less than 50 on the SELF-rated Anxiety scale/Self-rated Depression scale was considered normal; A score of 50-60 was mild anxiety; A score of 61 to 70 indicates moderate anxiety, while a score of 70 or more indicates severe anxiety.) 5) Long-term use of painkillers or overuse of painkillers (more than 10 days in a month); 6) Suspected or confirmed history of smoking, alcohol and drug abuse; 7) Women who have positive pregnancy test, are pregnant or breast-feeding, or plan to have a pregnancy; 8) allergic constitution and known allergic to the composition of the drug; 9) Participants in other clinical trials or participants in clinical trials within 3 months prior to screening; 10) Patients with coagulation dysfunction and previous thrombotic diseases; 11) Those who are considered unsuitable for the clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| remission rate of EAPP; | — |
Secondary
| Measure | Time frame |
|---|---|
| CA125;TCM syndrome score;COX-Menstrual symptom score;VAS, DYS, NMPP of EAPP;EHP-5; | — |
Countries
China
Contacts
Public ContactYu-Chaoqin
Naval Medical University
Outcome results
None listed